{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T02:40:38Z","timestamp":1779331238649,"version":"3.51.4"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["75N93019C00072"],"award-info":[{"award-number":["75N93019C00072"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI169207"],"award-info":[{"award-number":["AI169207"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI125160"],"award-info":[{"award-number":["R01AI125160"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32A1075090"],"award-info":[{"award-number":["T32A1075090"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["MR\/R005850\/1"],"award-info":[{"award-number":["MR\/R005850\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007812","name":"University of Washington","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020884","name":"QIAGEN","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016270","name":"GCRF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016270","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ijid.2023.03.035","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T01:57:39Z","timestamp":1679536659000},"page":"S47-S51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"S1","title":["Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis?"],"prefix":"10.1016","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5034-9727","authenticated-orcid":false,"given":"Sasha E.","family":"Larsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4543-9239","authenticated-orcid":false,"given":"Susan L.","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6974-5666","authenticated-orcid":false,"given":"Rhea N.","family":"Coler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2023.03.035_bib0001","unstructured":"World Health Organization. Global TB report 2022. Geneva: World Health Organization, 2022."},{"key":"10.1016\/j.ijid.2023.03.035_bib0002","unstructured":"Our World in Data. Daily confirmed COVID-19 deaths by world region, https:\/\/ourworldindata.org\/grapher\/daily-covid-deaths-region; 2023 [accessed 19 January 2023]."},{"key":"10.1016\/j.ijid.2023.03.035_bib0003","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1080\/21645515.2016.1205769","article-title":"Systematic review of mathematical models exploring the epidemiological impact of future TB vaccines","volume":"12","author":"Harris","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.ijid.2023.03.035_bib0004","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S2213-2600(19)30040-2","article-title":"The way forward for tuberculosis vaccines","volume":"7","author":"White","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ijid.2023.03.035_bib0005","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax4607","article-title":"Potential impact of tuberculosis vaccines in China, South Africa, and India","volume":"12","author":"Harris","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ijid.2023.03.035_bib0006","year":"2022","journal-title":"An investment case for new tuberculosis vaccines"},{"key":"10.1016\/j.ijid.2023.03.035_bib0007","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/S2666-5247(22)00303-2","article-title":"The role of bacterial vaccines in the fight against antimicrobial resistance: an analysis of the preclinical and clinical development pipeline","volume":"4","author":"Frost","year":"2023","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.ijid.2023.03.035_bib0008","series-title":"COVID-19 vaccine tracker and landscape","year":"2023"},{"key":"10.1016\/j.ijid.2023.03.035_bib0009","unstructured":"COVID-19 vaccine tracker. Vaccines Candidates in Clinical Trials, https:\/\/covid19.trackvaccines.org\/vaccines\/; 2023 [accessed 13 March 2023]."},{"key":"10.1016\/j.ijid.2023.03.035_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2020.101431","article-title":"Key recent advances in TB vaccine development and understanding of protective immune responses against Mycobacterium tuberculosis","volume":"50","author":"Scriba","year":"2020","journal-title":"Semin Immunol"},{"key":"10.1016\/j.ijid.2023.03.035_bib0011","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S2213-2600(20)30319-2","article-title":"Safety and immunogenicity of the adjunct therapeutic vaccine ID93\u2008+\u2008GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"9","author":"Day","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ijid.2023.03.035_bib0012","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41541-018-0057-5","article-title":"The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial","volume":"3","author":"Coler","year":"2018","journal-title":"npj Vaccines"},{"key":"10.1016\/j.ijid.2023.03.035_bib0013","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-2600(18)30077-8","article-title":"Safety and immunogenicity of the novel tuberculosis vaccine ID93\u2008+\u2008GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial","volume":"6","author":"Penn-Nicholson","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ijid.2023.03.035_bib0014","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/j.vaccine.2012.05.035","article-title":"Improved CD4(+) T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72\/AS01 as compared to the M72\/AS02 and Mtb72F\/AS02 tuberculosis candidate vaccine formulations: a randomized trial","volume":"31","author":"Leroux-Roels","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2023.03.035_bib0015","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.vaccine.2015.05.088","article-title":"Safety and immunogenicity of candidate vaccine M72\/AS01E in adolescents in a TB endemic setting","volume":"33","author":"Penn-Nicholson","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2023.03.035_bib0016","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1803484","article-title":"Phase 2b controlled trial of M72\/AS01E vaccine to prevent tuberculosis","volume":"379","author":"Van Der Meeren","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2023.03.035_bib0017","doi-asserted-by":"crossref","first-page":"6622","DOI":"10.1128\/IAI.72.11.6622-6632.2004","article-title":"The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs","volume":"72","author":"Brandt","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.ijid.2023.03.035_bib0018","doi-asserted-by":"crossref","first-page":"7618","DOI":"10.4049\/jimmunol.172.12.7618","article-title":"Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein","volume":"172","author":"Skeiky","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.ijid.2023.03.035_bib0019","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1073\/pnas.0712077106","article-title":"Defined tuberculosis vaccine, Mtb72F\/AS02A, evidence of protection in cynomolgus monkeys","volume":"106","author":"Reed","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijid.2023.03.035_bib0020","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nm.4473","article-title":"Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine","volume":"24","author":"Hansen","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ijid.2023.03.035_bib0021","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3390\/tropicalmed8020089","article-title":"Challenges and the way forward in diagnosis and treatment of tuberculosis infection","volume":"8","author":"Chin","year":"2023","journal-title":"Trop Med Infect Dis"},{"key":"10.1016\/j.ijid.2023.03.035_bib0022","doi-asserted-by":"crossref","first-page":"7948","DOI":"10.4049\/jimmunol.181.11.7948","article-title":"Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis","volume":"181","author":"Bertholet","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.ijid.2023.03.035_bib0023","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3390\/vaccines11010130","article-title":"An RNA-based vaccine platform for use against Mycobacterium tuberculosis","volume":"11","author":"Larsen","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ijid.2023.03.035_bib0024","doi-asserted-by":"crossref","first-page":"e67016","DOI":"10.1371\/journal.pone.0067016","article-title":"Human Mycobacterium tuberculosis CD8 T cell antigens\/epitopes identified by a proteomic peptide library","volume":"8","author":"Lewinsohn","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2023.03.035_bib0025","doi-asserted-by":"crossref","first-page":"6218","DOI":"10.4049\/jimmunol.166.10.6218","article-title":"Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene","volume":"166","author":"Cheng","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.ijid.2023.03.035_bib0026","doi-asserted-by":"crossref","first-page":"11371","DOI":"10.1073\/pnas.93.21.11371","article-title":"Alphavirus-based expression vectors: strategies and applications","volume":"93","author":"Frolov","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijid.2023.03.035_bib0027","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.ijid.2023.03.035_bib0028","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ijid.2023.03.035_bib0029","doi-asserted-by":"crossref","first-page":"6324","DOI":"10.1128\/IAI.72.11.6324-6329.2004","article-title":"RNA encoding the MPT83 antigen induces protective immune responses against Mycobacterium tuberculosis infection","volume":"72","author":"Xue","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.ijid.2023.03.035_bib0030","doi-asserted-by":"crossref","first-page":"e10060","DOI":"10.1002\/amp2.10060","article-title":"Rapid development and deployment of high-volume vaccines for pandemic response","volume":"2","author":"Kis","year":"2020","journal-title":"J Adv Manuf Process"},{"key":"10.1016\/j.ijid.2023.03.035_bib0031","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics\u2013developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ijid.2023.03.035_bib0032","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/nyas.14235","article-title":"Vaccine innovations for emerging infectious diseases-a symposium report","volume":"1462","author":"Cable","year":"2020","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ijid.2023.03.035_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.840225","article-title":"It takes a village: the multifaceted immune response to Mycobacterium tuberculosis infection and vaccine-induced immunity","volume":"13","author":"Larsen","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijid.2023.03.035_bib0034","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3390\/vaccines11010087","article-title":"Safety, efficacy, and immunogenicity of varying types of COVID-19 vaccines in children younger than 18 years: an update of systematic review and meta-analysis","volume":"11","author":"Tian","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ijid.2023.03.035_bib0035","article-title":"Safety monitoring of COVID-19 vaccines: perspective from the European Medicines Agency","author":"Durand","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijid.2023.03.035_bib0036","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/j.ymthe.2018.07.010","article-title":"A nanostructured lipid carrier for delivery of a replicating viral RNA provides single, low-dose protection against Zika","volume":"26","author":"Erasmus","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.ijid.2023.03.035_bib0037","doi-asserted-by":"crossref","first-page":"9040","DOI":"10.1038\/s41598-021-88291-8","article-title":"Subunit vaccine protects against a clinical isolate of Mycobacterium avium in wild type and immunocompromised mouse models","volume":"11","author":"Larsen","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijid.2023.03.035_bib0038","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc9396","article-title":"An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates","volume":"12","author":"Erasmus","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ijid.2023.03.035_bib0039","article-title":"Adverse reactions after the third dose of the BNT162b2 mRNA COVID-19 vaccine among medical school residents in a regional reference university hospital in Italy","volume":"10","author":"Rahmani","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ijid.2023.03.035_bib0040","doi-asserted-by":"crossref","DOI":"10.4093\/dmj.2022.0129","article-title":"Safety of COVID-19 vaccines among patients with type 2 diabetes mellitus: real-world data analysis","author":"Kim","year":"2023","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.ijid.2023.03.035_bib0041","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA COVID-19 vaccine in a nationwide setting","volume":"385","author":"Barda","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2023.03.035_bib0042","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.hfc.2022.08.012","article-title":"Myocarditis following COVID-19 vaccination","volume":"19","author":"Marschner","year":"2023","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.ijid.2023.03.035_bib0043","doi-asserted-by":"crossref","first-page":"e75537","DOI":"10.7554\/eLife.75537","article-title":"SARS-CoV-2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern","volume":"11","author":"Hawman","year":"2022","journal-title":"eLife"},{"key":"10.1016\/j.ijid.2023.03.035_bib0044","doi-asserted-by":"crossref","unstructured":"O\u00e2 Connor MA, Hawman DW, Meade-White K, Leventhal S, Song W, Randall S, et\u00a0al. A replicon RNA vaccine induces durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned. bioRxiv, https:\/\/www.biorxiv.org\/content\/10.1101\/2022.08.08.503239v1; 09 August 2022 [accessed 13 March 2023].","DOI":"10.1101\/2022.08.08.503239"},{"key":"10.1016\/j.ijid.2023.03.035_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.tube.2022.102302","article-title":"Immunogenicity and protection against Mycobacterium avium with a heterologous RNA prime and protein boost vaccine regimen","volume":"138","author":"Rais","year":"2023","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.ijid.2023.03.035_bib0046","unstructured":"United Nations Children's Fund (UNICEF). Vaccines bring 7 diseases under control, https:\/\/www.unicef.org\/pon96\/hevaccin.htm; 2019 [accessed 24 October 2019]."}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971223001145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971223001145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T16:35:39Z","timestamp":1746376539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971223001145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":46,"alternative-id":["S1201971223001145"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2023.03.035","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis?","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2023.03.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}